We already knew that GSK R&D chief Hal Barron got paid considerably more than his boss, Emma Walmsley — who’s at the bottom of the list of major league biopharma CEOs when it comes to compensation. It turns out he also gets a much bigger travel budget.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.Free Subscription